Background: Severe malaria is a medical emergency with high mortality. Prompt achievement of therapeutic concentrations of highly effective anti-malarial drugs reduces the risk of death. The aim of this study was to assess the pharmacokinetics and pharmacodynamics of intravenous artesunate in Ugandan adults with severe malaria.
Methods: Fourteen adults with severe falciparum malaria requiring parenteral therapy were treated with 2.4 mg/kg intravenous artesunate. Blood samples were collected after the initial dose and plasma concentrations of artesunate and dihydroartemisinin measured by solid-phase extraction and liquid chromatography-tandem mass spectrometry. The study was approved by the Makerere University Faculty of Medicine Research and Ethics Committee (Ref2010-015) and Uganda National Council of Science and Technology (HS605) and registered with ClinicalTrials.gov (NCT01122134).
Results: All study participants achieved prompt resolution of symptoms and complete parasite clearance with median (range) parasite clearance time of 17 (8-24) hours. Median (range) maximal artesunate concentration (Cmax) was 3260 (1020-164000) ng/mL, terminal elimination half-life (T1/2) was 0.25 (0.1-1.8) hours and total artesunate exposure (AUC) was 727 (290-111256) ng·h/mL. Median (range) dihydroartemisinin Cmax was 3140 (1670-9530) ng/mL, with Tmax of 0.14 (0.6 - 6.07) hours and T1/2 of 1.31 (0.8-2.8) hours. Dihydroartemisinin AUC was 3492 (2183-6338) ng·h/mL. None of the participants reported adverse events.
Conclusions: Plasma concentrations of artesunate and dihydroartemisinin were achieved rapidly with rapid and complete symptom resolution and parasite clearance with no adverse events.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489518 | PMC |
http://dx.doi.org/10.1186/1475-2875-11-132 | DOI Listing |
Cureus
December 2024
Clinical Pathology and Laboratory Department, Bekaa Hospital, Bekaa, LBN.
Malaria, a mosquito-borne disease caused by five plasmodium species, still has a life-threatening risk worldwide. Clinical manifestations can range from mild nonspecific symptoms to severe disease. In non-endemic regions, sporadic cases frequently pose significant challenges to health workers as delayed diagnosis can lead to serious consequences and even death.
View Article and Find Full Text PDFParasitol Int
January 2025
Infectious Diseases Division, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Iran J Parasitol
January 2024
Department of Internal Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey.
In patients presenting with post-malarial anemia following intravenous artesunate treatment, post-artesunate delayed hemolysis should be considered in the differential diagnosis, even in endemic settings. Close monitoring for signs of delayed hemolysis in patients previously treated with intravenous artesunate for severe malaria, regardless of their malaria exposure history or geographic location is crucial.
View Article and Find Full Text PDFCureus
November 2024
Infectious Diseases, Harlem Hospital Center, New York, USA.
Malaria is an infection caused by five different Plasmodium species. The most common are is more rarely reported and mostly has a benign course. We present a case of a 40-year-old male with a six-day history of headaches, chills, and fever who was initially evaluated in our emergency room, from where he was discharged after a negative workup for malaria.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!